At the beginning of nineties, the treatment of high-risk radically resected colon cancer changed dramatically: in fact, the 1990 NIH Consensus Conference suggested an adjuvant 5-fluorouracil-based chemotherapy as the standard of care for all medically fit patients with resected stage III colon cancer. The same treatment could be considered also in patients with high-risk stage II disease; high-risk patients were defined by pathological factors such as a small number of sampled lymph nodes, T4 lesions, perforation or poorly differentiated histology [1].
Adjuvant chemotherapy in colon cancer: can we improve quality of care? / Cascinu, Stefano. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - 45:8(2013), pp. 637-638. [10.1016/j.dld.2013.04.011]
Adjuvant chemotherapy in colon cancer: can we improve quality of care?
CASCINU, Stefano
2013
Abstract
At the beginning of nineties, the treatment of high-risk radically resected colon cancer changed dramatically: in fact, the 1990 NIH Consensus Conference suggested an adjuvant 5-fluorouracil-based chemotherapy as the standard of care for all medically fit patients with resected stage III colon cancer. The same treatment could be considered also in patients with high-risk stage II disease; high-risk patients were defined by pathological factors such as a small number of sampled lymph nodes, T4 lesions, perforation or poorly differentiated histology [1].
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
